Not too long ago, some had written off the potential for significant growth to resume in sales of the little wire mesh tubes that are painted with special drugs to help keep arteries from reclogging.   Read More

Cramer makes the call on viewers' favorite stocks.   Read More

Leerink Swann, which specializes in healthcare equities research, is out with a couple of noteworthy surveys--one on the collateral damage to Merck and Schering-Plough's Vytorin this week and the other on drug-coated stents from Abbott Labs, Boston Scientific, Johnson & Johnson and Medtronic.    Read More

In Wednesday’s Web Extra Pete Najarian reveals why he thinks the solar trade is starting to turn. Also “if you want to get into drugs” Guy Adami has your play.   Read More

Which is the Street more worried about--declining stock prices, particularly for financials, or inflation? It's both, and this morning's action illustrates that concern. It's been a roller coaster of a morning, up on Wells Fargo, down on consumer inflation higher than expected.    Read More

Oil's move could be a key trend in Wednesday's markets, as traders watch more Fed testimony, a bunch of earnings reports and another helping of inflation data.    Read More

At a time of market uncertainty, what can an investor count on?  Knee replacements, for one thing.  Bruce Nudell, UBS senior research analyst, takes that as his cue in picking some promising stocks.   Read More

The debate about whether stocks are finding a floor is gaining momentum, but traders agree it's the earnings season that will help decide the details.    Read More

Some traders are also turning bullish. John Mendelson of the Stanford Group issued a buy signal late in the day; traders tell me it was his 3rd buy signal in 5 years, and the prior two calls were very good.   Read More

So, I can now safely say, with complete confidence, that Food and Drug Administration approval of the new Abbott drug-coated stent will not happen in the second quarter. Recently, at least a couple of analysts have been telling clients a decision was getting pushed out until the third quarter and one suggested that Xience won't be launched until Q4.   Read More